National Comprehensive Cancer Network ( NCCN ) of the united states has updated its 2nd version of 2017 guideline on the clinical management of bone cancer. Some minor revisions have been updated in terms of the radiological examination and the Ewing sarcoma terminology, and a major revision regarding the change of 'considering second line chemotherapy ( 2B )' to 'maintain original chemotherapy or consider second line chemotherapy ( 2B )', while no remarkable renewals were seen in the remaining content of NCCN bone cancer guideline. Given the effortless endeavor toward the clinical and basic research, the prognosis of primary high-grade bone malignancy has reached a plateau in the past three decades. In this article, we aim to discuss, together with recent evidence, the updated NCCN bone cancer guideline from chemotherapy, molecular biomarker, target agents, metastatic heterogeneity and metastasectomy, and suggest our future directions for the treatment of osteosarcoma and Ewing sarcoma.

作者：鲍其远；王际壮；温竣翔；沈宇辉；张伟滨

来源：中国骨与关节杂志 2018 年 7卷 1期